keyword
MENU ▼
Read by QxMD icon Read
search

recurrent risk factors hepatocellular carcinoma

keyword
https://www.readbyqxmd.com/read/29340726/prognostic-prediction-models-for-resection-of-large-hepatocellular-carcinoma-a-korean-multicenter-study
#1
Shin Hwang, Jae-Won Joh, Hee Jung Wang, Dong Goo Kim, Kyung Sik Kim, Kyung-Suk Suh, Seong Hoon Kim, Hee Chul Yu, Chol Kyoon Cho, Young-Joo Lee, Ki-Hun Kim, Jong Man Kim, Bong-Wan Kim, Sung-Gyu Lee
BACKGROUND: We developed a prognostic prediction model (PPM) using 4 factors for hepatic resection (HR) of large hepatic cellular carcinoma (HCC). Multiplication of α-fetoprotein (AFP), des-γ-carboxy prothrombin, and tumor volume (TV) (ADV score) is a surrogate marker for post-resection prognosis. This study intended to validate the predictive power of 4-factor PPM and to develop new ADV score-based PPM. METHODS: A total of 526 patients who underwent HR for solitary HCC ≥ 8 cm were selected from 9 Korean institutions between 2008 and 2014...
January 16, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29331341/effects-of-the-gut-liver-axis-on-ischemia-mediated-hepatocellular-carcinoma-recurrence-in-the-mouse-liver
#2
Lorenzo A Orci, Stéphanie Lacotte, Vaihere Delaune, Florence Slits, Graziano Oldani, Vladimir Lazarevic, Carlo Rossetti, Laura Rubbia-Brandt, Philippe Morel, Christian Toso
BACKGROUND & AIMS: There is growing evidence that liver graft ischemia-reperfusion (I/R) is a risk factor for hepatocellular carcinoma (HCC) recurrence, but the involved mechanisms are unclear. Here, we tested the hypothesis that mesenteric congestion due to portal blood flow interruption induces endotoxin-mediated Toll-Like Receptor 4 (Tlr4) engagement, resulting in elevated liver cancer burden. We also assessed the role of remote ischemic preconditioning (RIPC) in this context. METHODS: C57Bl/6j mice were exposed to standardized models of liver I/R injury and RIPC, by occluding hepatic and femoral blood vessels...
January 10, 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/29316069/entecavir-and-tenofovir-reduce-hepatitis-b-virus-related-hepatocellular-carcinoma-recurrence-more-effectively-than-other-antivirals
#3
Hyeki Cho, Hongkeun Ahn, Dong Hyeon Lee, Jeong-Hoon Lee, Yong Jin Jung, Young Chang, Joon Yeul Nam, Young Youn Cho, Dong Ho Lee, Eun Ju Cho, Su Jong Yu, Jeong Min Lee, Yoon Jun Kim, Jung-Hwan Yoon
Nucleos(t)ide analogues (NAs) have been shown to decrease the risk of hepatocellular carcinoma (HCC) recurrence. This study evaluated whether high-potency NAs (entecavir and tenofovir disoproxil fumarate [TDF]) reduce the risk of tumor recurrence more potently than low-potency NAs after curative treatment of hepatitis B virus (HBV)-related HCC. This study included 607 consecutive HBV-related HCC patients treated with surgical resection or radiofrequency ablation. The patients were categorized into three groups according to antiviral treatment: group A (no antiviral; n=261), group B (low-potency NA; n=90), and group C (high-potency NA; n=256)...
January 6, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29313290/impact-of-preoperative-hepatitis-b-virus-levels-on-prognosis-after-primary-and-repeat-hepatectomies-for-hepatocellular-carcinoma-patients-a-retrospective-study
#4
Pin-Gao Yan, Ruo-Yu Wang, Jin Zhang, Wen-Ming Cong, Hui Dong, Hong-Yu Yu, Wan Yee Lau, Meng-Chao Wu, Wei-Ping Zhou
BACKGROUND: Chronic HBV plays an important role in hepatocellular carcinoma pathogenesis. Previously, most studies have been focusing on HBV DNA levels before the primary curative hepatectomy. However, the association of virus level before repeat hepatectomy with the degrees of inflammation and fibrosis on histopathology and prognosis has not been surveyed. METHODS: From January 2002 to December 2009, all patients who were seropositive for hepatitis B surface antigen (HBsAg) were enrolled and assigned into four groups based on their HBV DNA levels before the primary and repeat hepatectomies...
January 8, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29299157/management-of-intrahepatic-recurrence-after-resection-for-hepatocellular-carcinoma-exceeding-the-barcelona-clinic-liver-cancer-criteria
#5
Wei Xu, Rui Guo, Gang Xu, Lejia Sun, Dandan Hu, Haifeng Xu, Huayu Yang, Xinting Sang, Xin Lu, Yilei Mao
Background: Although patients with Barcelona clinic liver cancer stage B or C hepatocellular carcinoma derive survival benefit from hepatectomy, prognostic factors and management after curative resection are unclear. This study aims to evaluate predictive factors, therapy and prognosis of intra-hepatic recurrences after curative resection of Barcelona clinic liver cancer stage B or C hepatocellular carcinoma. Methods: We retrospectively analyzed 397 patients with Barcelona clinic liver cancer stage B or C hepatocellular carcinoma who underwent curative resections from January 1989 to October 2011...
December 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/29282384/hepatocyte-nuclear-factor-1%C3%AE-mutated-hepatocellular-adenomas-an-atypical-presentation
#6
Camila Maria Neves Sousa, Patricia Maria Miranda Gadelha, Rafaella de Sousa Cartaxo, George Washington Holanda Pedrosa, Rodrigo Schuler Honorio, José Milton de Castro Lima, Gustavo Rêgo Coelho, Clovis Rêgo Coelho
Hepatocellular adenomas (HCAs) are rare benign monoclonal hepatic tumors that commonly occur in females (3-4 per 100,000 women) due to the use of oral contraceptives, its primary risk factor. Recently, HCAs have been classified into 4 distinct subtypes according to genotypic and phenotypic characteristics and clinical features: inflammatory HCA (40-50%), which are hypervascular with marked peliosis and a tendency to bleed; hepatocyte nuclear factor 1α (HNF1A)-mutated HCA (H-HCA, 30-40%) that are diffusely steatotic and rarely undergo malignant transformation; β-catenin activated HCA (10-15%), which frequently undergo malignant transformation and may seem hepatocellular carcinoma on imaging; and unclassified HCA (10-25%)...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29258507/prognostic-significance-of-microvascular-invasion-in-tumor-stage-for-hepatocellular-carcinoma
#7
Yong Keun Park, Sung Kyu Song, Bong-Wan Kim, Seung-Keun Park, Chul-Woon Chung, Hee-Jung Wang
BACKGROUND: The presence of microvascular invasion (McVI) in hepatocellular carcinoma (HCC) has been proposed as a cause of recurrence and poor survival, although this has not been officially emphasized in staging systems. Thus, we conducted a retrospective study to investigate the prognostic importance of McVI in tumor staging in patients with HCC who underwent hepatic resection. METHODS: A retrospective analysis was performed of patients who underwent hepatic resection for HCC at our center from 1994 to 2012...
December 19, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29251164/value-of-hcc-meld-score-in-patients-with-hepatocellular-carcinoma-undergoing-liver-transplantation
#8
Gian Piero Guerrini, Domenico Pinelli, Elena Marini, Vittorio Corno, Michela Guizzetti, Marco Zambelli, Alessandro Aluffi, Lisa Lincini, Stefano Fagiuoli, Alessandro Lucianetti, Michele Colledan
CONTEXT: Liver transplantation (LT) is considered the ideal therapy for patients with hepatocellular carcinoma (HCC) having cirrhosis but the shortage of liver donors and the risk of dropout from the wait list due to tumor progression severely limit transplantation. A new prognostic score, the HCC-model for end-stage liver disease (HCC-MELD), was developed by combining α-fetoprotein (AFP), MELD, and tumor size, to improve risk stratification of dropout in patients with HCC. OBJECTIVES: In this study, we investigated the ability of the HCC-MELD score in predicting the posttransplant for patients fulfilling Milan criteria (MC)...
January 1, 2017: Progress in Transplantation
https://www.readbyqxmd.com/read/29244227/surveillance-for-hepatobiliary-cancers-in-patients-with-primary-sclerosing-cholangitis
#9
Ahmad Hassan Ali, James H Tabibian, Navine Naser-Ghodsi, Ryan J Lennon, Thomas DeLeon, Mitesh J Borad, Moira Hilscher, Marina G Silveira, Elizabeth J Carey, Keith D Lindor
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a risk factor for cholangiocarcinoma (CCA) and gallbladder carcinoma (GBCa). Surveillance for GBCa is recommended, but the clinical utility of surveillance for other hepatobiliary cancers (HBCa) in PSC, namely CCA and hepatocellular carcinoma (HCC), is unclear. We aimed to determine whether surveillance is associated with better survival after diagnosis of HBCa in patients with PSC. METHODS: Medical records of PSC patients seen at Mayo Clinic Rochester from 1995-2015 were reviewed...
December 15, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29221801/donor-polymorphisms-of-toll-like-receptor-4-rs1927914-associated-with-the-risk-of-hepatocellular-carcinoma-recurrence-following-liver-transplantation
#10
Guangjun Shi, Chuanxu Wang, Ping Zhang, Lisha Ji, Shifeng Xu, Xueying Tan, Hao Li
BACKGROUND: Hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) severely restricts the long-term survival of patients. Toll-like receptor 4 (TLR4) has been considered to be involved in hepatocarcinogenesis and metastasis. Additionally, there is a study demonstrating the significant association between TLR4 gene rs1927914 polymorphism and HCC, but no study investigated the association of the TLR4 rs1927914 polymorphism with the risk of HCC recurrence following LT...
December 5, 2017: Archives of Medical Research
https://www.readbyqxmd.com/read/29221172/the-prognostic-value-of-inflammation-based-scores-in-advanced-hepatocellular-carcinoma-patients-prior-to-treatment-with-sorafenib
#11
Guillaume Conroy, Julia Salleron, Arthur Belle, Mouni Bensenane, Abdelbasset Nani, Ahmet Ayav, Didier Peiffert, Anthony Lopez, Cédric Baumann, Hélène Barraud, Jean-Pierre Bronowicki
Background and Aims: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sorafenib-treated HCC patients. Various inflammation-based scores (IBSs) have been evaluated as predictors of tumor recurrence and survival in various malignancies (including HCC). The objective of the present study was to determine the prognostic value of IBSs for overall survival (OS) in advanced HCC patients prior to the initiation of sorafenib therapy...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29217359/impact-of-tumor-size-on-the-prognosis-of-hepatocellular-carcinoma-in-patients-who-underwent-liver-resection
#12
Chia-Yen Dai, Ching-Yeh Lin, Pei-Chien Tsai, Ping-Yi Lin, Ming-Lun Yeh, Chung-Feng Huang, Wen-Tsan Chang, Jee-Fu Huang, Ming-Lung Yu, Yao-Li Chen
BACKGROUND: Health burdens of hepatocellular carcinoma (HCC) are emerging quickly in the world, including in Taiwan. Surgical resection has been recognized as the first-line treatment for early tumors. This study aimed to investigate the prognostic risk factors for mortality and recurrence rate in Taiwan, which has a high prevalence of chronic viral hepatitis. METHODS: A total of 397 HCC patients receiving tumor resection were consecutively examined in central Taiwan from 2008 to 2014...
December 4, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/29212479/a-pilot-systematic-genomic-comparison-of-recurrence-risks-of-hepatitis-b-virus-associated-hepatocellular-carcinoma-with-low-and-high-degree-liver-fibrosis
#13
Seungyeul Yoo, Wenhui Wang, Qin Wang, M Isabel Fiel, Eunjee Lee, Spiros P Hiotis, Jun Zhu
BACKGROUND: Chronic hepatitis B virus (HBV) infection leads to liver fibrosis, which is a major risk factor in hepatocellular carcinoma (HCC) and an independent risk factor of recurrence after HCC tumor resection. The HBV genome can be inserted into the human genome, and chronic inflammation may trigger somatic mutations. However, how HBV integration and other genomic changes contribute to the risk of tumor recurrence with regards to the different degree of liver fibrosis is not clearly understood...
December 7, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29206595/assessment-of-response-to-transcatheter-arterial-chemoembolization-with-doxorubicin-eluting-microspheres-tumor-biology-and-hepatocellular-carcinoma-recurrence-in-a-5-year-transplant-cohort
#14
Tyler A Sandow, Stephen E Arndt, Abeer A Albar, Daniel A DeVun, David S Kirsch, Juan M Gimenez, Humberto E Bohorquez, Patrick J Gilbert, Paul T Thevenot, Kelley G Nunez, Gretchen A Galliano, Ari J Cohen, Dennis Kay, Paul M Gulotta
Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016...
December 4, 2017: Radiology
https://www.readbyqxmd.com/read/29179180/neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-ratio-as-prognostic-predictors-for-hepatocellular-carcinoma-patients-with-various-treatments-a-meta-analysis-and-systematic-review
#15
Jun Zheng, Jianye Cai, Hui Li, Kaining Zeng, Liying He, Hongyuan Fu, Jiebin Zhang, Liang Chen, Jia Yao, Yingcai Zhang, Yang Yang
BACKGROUND/AIMS: Systemic inflammatory response (SIR) is widely considered as a preoperative risk factor for hepatocellular carcinoma (HCC) outcomes. The neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), two of the prognostic indices, have been investigated in post-therapeutic recurrence and survival of HCC. Here, we quantify the prognostic value of these two biomarkers and evaluate their consistency in different HCC therapies. METHODS: A systematic review of electronic database of the Web of Science, Embase, PubMed and the Cochrane Library was conducted to search for associations between the NLR and PLR in the blood and clinical outcomes of HCC...
2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29176777/risk-of-recurrence-in-chronic-hepatitis-b-patients-developing-hepatocellular-carcinoma-with-antiviral-secondary-prevention-failure
#16
I-Cheng Lee, Gar-Yang Chau, Yi-Chen Yeh, Yee Chao, Teh-Ia Huo, Chien-Wei Su, Han-Chieh Lin, Ming-Chih Hou, Yi-Hsiang Huang
BACKGROUND: Nucleos(t)ide analogues (NUCs) treatment can reduce the risk of hepatocellular carcinoma (HCC) development and recurrence in chronic hepatitis B (CHB) patients. However, the risk of recurrence in CHB patients who develop HCC despite NUC treatment remains unclear. METHODS: 167 consecutive CHB patients receiving curative resection for HCC with NUC therapy after surgery were retrospectively enrolled. Thirty-eight patients who developed HCC despite NUC therapy for more than 1 year were defined as secondary prevention failure...
2017: PloS One
https://www.readbyqxmd.com/read/29175528/excellent-outcomes-of-liver-transplantation-following-down-staging-of-hepatocellular-carcinoma-to-within-milan-criteria-a-multi-center-study
#17
Neil Mehta, Jennifer Guy, Catherine T Frenette, Jennifer L Dodge, Robert W Osorio, William B Minteer, John P Roberts, Francis Y Yao
BACKGROUND & AIMS: Single-center studies have reported excellent outcomes of patients who underwent liver transplantation for hepatocellular carcinoma (HCC) after successful down-staging (reduction of tumor burden with local-regional therapy), but multi-center studies are lacking. We performed a multi-center study, applying a uniform down-staging protocol, to assess outcomes of liver transplantation and performed an intention to treat analysis. We analyzed factors associated with treatment failure, defined as dropout from the liver transplant waitlist due to tumor progression, liver-related death without transplant, or recurrence of HCC after transplant...
November 23, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29159757/correlation-between-postoperative-early-recurrence-of-hepatocellular-carcinoma-and-mesenchymal-circulating-tumor-cells-in-peripheral-blood
#18
Zhong Wang, Lei Luo, Yuan Cheng, Guolin He, Bangjian Peng, Yi Gao, Ze-Sheng Jiang, MingXin Pan
BACKGROUND: Circulating tumor cells (CTCs) have been actively studied for their functions in hepatocellular carcinoma (HCC) recurrence. However, the relationship between circulating tumor cells subtypes and hepatocellular carcinoma recurrence is still unclear. METHODS: CTCs were collected from the peripheral blood of 62 postoperative HCC patients. The CTCs were isolated with a filtration-based method. Multiplex fluorescence in situ hybridization was used to characterize the CTCs based on mRNA expression levels of epithelial and mesenchymal markers...
November 20, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29156744/changes-of-alpha-fetoprotein-levels-could-predict-recurrent-hepatocellular-carcinoma-survival-after-trans-arterial-chemoembolization
#19
Chao He, Xiaoyun Zhang, Chuan Li, Wei Peng, Tian-Fu Wen, Lv-Nan Yan, Jiayin Yang, Wusheng Lu
Background: There is paucity of information concerning whether AFP change is a predictor of prognosis for recurrent hepatocellular carcinoma (RHCC) patients after trans-arterial chemoembolization (TACE). Methods: A total of 177 RHCC patients who received TACE as first-line therapy were retrospectively analyzed. The patients were classified into three groups according to their pre-TACE and post-TACE AFP levels (group A: AFP decreased, group B: AFP consistent normal, and group C: AFP increased)...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151695/efficacy-of-postoperative-adjuvant-transcatheter-arterial-chemoembolization-in-hepatocellular-carcinoma-patients-with-microvascular-invasion
#20
Jia-Zhou Ye, Jun-Ze Chen, Zi-Hui Li, Tao Bai, Jie Chen, Shao-Liang Zhu, Le-Qun Li, Fei-Xiang Wu
AIM: To investigate the efficacy and safety of postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) in preventing tumor recurrence and improving survival in Barcelona Clinic Liver Cancer (BCLC) early (A) and intermediate (B) stage hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI). METHODS: A total of 519 BCLC A or B HCC patients treated by liver resection alone or followed by PA-TACE between January 2012 and December 2015 were studied retrospectively...
November 7, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
62100
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"